Cencora stock: Barclays lifts price target to 415 dollars
Published on 11/19/2026 at 15:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Barclays raised its Cencora price target while retaining an Overweight rating.
- The bank considers Cencora's initial fiscal 2027 outlook reasonable.
- Barclays cited a 16 percent discount to drug distributors and broadly positive fundamentals.
Barclays raised its Cencora price target on Wednesday, November 18, while keeping an Overweight rating on the shares. Markets Insider reported that analyst Glen Santangelo lifted the target from 350 to 415 US dollars after reviewing Cencora's fiscal 2027 outlook.
Barclays changes valuation view
Barclays described Cencora's initial fiscal 2027 outlook as reasonable and kept its Overweight view. The analyst said Cencora had underperformed drug distributors year to date.
Discount remains in focus
The research note said Cencora traded at a 16 percent discount to drug distributors. Barclays expects that discount to narrow if fundamentals remain broadly positive across the business.
Cencora stock traded at 312.85 euros on Lang & Schwarz at 15:41 CET on Thursday, November 19.
Cencora Inc. at a glance
- ISIN: US03073E1055
- Trading venue: Lang & Schwarz
- Price: 312.85 euros at 15:41 CET on November 19, 2026
- Analyst action: Barclays target raised from 350 to 415 US dollars; Overweight maintained
US equities remain in focus alongside Cencora's analyst-driven revaluation. See Current market reports for broader market coverage.
